- Potential benefitSpeeds transition from prototypes to production, reducing time to deploy medical countermeasures.
- Potential benefitEnables rapid purchase of experimental supplies and prototypes for testing and development.
- Potential benefitEncourages private investment by allowing follow-on awards to initial participants without rebidding.
FLASH Act of 2025
Referred to the House Committee on Energy and Commerce.
Amends section 319L of the Public Health Service Act to expand BARDA authorities: allow follow-on production contracts to prototype participants without new competition, permit procurement of supplies for experimental or test purposes using noncompetitive procedures, and authorize acquiring innovative commercial products and services via general solicitation with competitive proposal review. Adds limits and requirements: fixed-price contracts, a $100 million threshold requiring a written determination and congressional notification, and a definition of "innovative." Also clarifies prototypes include tests, prototypes, and animal models.
Speed versus competition: liberals/centrists value speed; conservatives worry about noncompetitive awards
Relative to its intended legislative type, this bill amends existing Public Health Service Act procurement authorities in a focused way: it provides specific legal mechanisms to allow follow-on production awards, experimental/test purchases, and acquisition of 'innovative' commercial products via general solicitation, and it incorporates several procedural limits (fixed-price, $100M threshold with written determination, congressional notification).
Amends section 319L of the Public Health Service Act to expand BARDA authorities: allow follow-on production contracts to prototype participants without new competition, permit procurement of supplies for experimental or test purposes using noncompetitive procedures, and authorize acquiring innovative commercial products and services via general solicitation with competitive proposal review.
Adds limits and requirements: fixed-price contracts, a $100 million threshold requiring a written determination and congressional notification, and a definition of "innovative." Also clarifies prototypes include tests, prototypes, and animal models.
Technical, limited-scope modernization of BARDA authorities improves speed; passage aided by bipartisan norms but depends on legislative vehicle and oversight concerns.
Relative to its intended legislative type, this bill amends existing Public Health Service Act procurement authorities in a focused way: it provides specific legal mechanisms to allow follow-on production awards, experimental/test purchases, and acquisition of 'innovative' commercial products via general solicitation, and it incorporates several procedural limits (fixed-price, $100M threshold with written determination, congressional notification).
Speed versus competition: liberals/centrists value speed; conservatives worry about noncompetitive awards
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenAuthorizes noncompetitive follow-on awards, potentially reducing market competition and favoring incumbents.
- Potential burdenExpanded noncompetitive procurement authorities increase risks of higher costs and reduced value for money.
- Potential burdenOnly awards over $100 million trigger mandatory congressional notice, limiting transparency for smaller large contracts.
Why the argument around this bill splits.
Speed versus competition: liberals/centrists value speed; conservatives worry about noncompetitive awards
Generally supportive of faster, more flexible federal tools to speed medical countermeasure development and public health preparedness, while wary of corporate capture and transparency gaps.
Sees potential public health benefits but would push for safeguards on pricing, access, and equitable distribution.
Cautiously favorable: pragmatic improvement to government procurement speed and flexibility for biodefense and public health.
Appreciates built-in limits and congressional notification but wants strong oversight, clear cost controls, and accountability rules.
Skeptical of expanding executive procurement authority and noncompetitive award exceptions; worries about increased federal discretion and potential waste.
Might accept efficiency gains but demands stricter limits, competition, and congressional control over large expenditures.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technical, limited-scope modernization of BARDA authorities improves speed; passage aided by bipartisan norms but depends on legislative vehicle and oversight concerns.
- No cost estimate or CBO score included
- Potential pushback over noncompetitive follow-on awards
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Speed versus competition: liberals/centrists value speed; conservatives worry about noncompetitive awards
Technical, limited-scope modernization of BARDA authorities improves speed; passage aided by bipartisan norms but depends on legislative ve…
Relative to its intended legislative type, this bill amends existing Public Health Service Act procurement authorities in a focused way: it provides specific legal mechanisms to allow follow-on production awards, experi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.